Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Lomvastomig

(Synonyms: RO 7121661, Lomvastomig (Anti-PD-1 & TIM-3), Lomvastomig) Copy Product Info
🥰Excellent

Synonyms: RO 7121661, Lomvastomig (Anti-PD-1 & TIM-3), Lomvastomig

Catalog No. T9901A-784 Copy Product Info
🥰Excellent
Lomvastomig is a bispecific antibody that targets PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune response. It is designed for cancer treatment by promoting T cell activation and overcoming immune suppression. [Molecular weight: 145.34 kDa]
Lomvastomig
Cas No. 2648840-52-0
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$4964-6 weeks4-6 weeks
5 mg$1,4804-6 weeks4-6 weeks
10 mg$2,3904-6 weeks4-6 weeks
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Lomvastomig is a bispecific antibody that targets PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune response. It is designed for cancer treatment by promoting T cell activation and overcoming immune suppression. [Molecular weight: 145.34 kDa]
SynonymsRO 7121661, Lomvastomig (Anti-PD-1 & TIM-3), Lomvastomig
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Chemical Properties
Cas No.2648840-52-0
Storage & Solubility Information
StorageStore at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion
Related Tags: